Lilonton medicine 1000mg/5ml Siuguanchem Symptomatic treatment of mental syndrome (10 tubes)

Dosage form 10 -tube box
Specifications Piracetam

Ingredient

Thành phần cho 5ml

Composition information	Content
Piracetam	1000mg

Uses

Indications

Lilonton Injection 1000mg/5ml drug is indicated in the following case:

Adults

Symptomatic treatment of mental syndrome - entity with improved characteristics by treatment such as: Memory loss, attention disorders and dynamic disorders.

Single or coordination in muscle vibration due to the cause of the cerebral cortex.

Dizziness treatment and accompanying balance disorders, except dizziness of vascular or mental origin.

Prevent and reduce the exacerbations in sickle cell disease.

Children

Symptomatic treatment is difficult to read, combined with appropriate measures such as: Language therapy.

Prevent and reduce the exacerbations in sickle cell disease.

Pharmacokinatus

Mechanism of action: It is unclear the mechanism of impact of piracetam on the muscle vibration of the cerebral cortex.

Piracetam shows the effect of blood flow changes to platelets, red blood cells and blood vessels due to increasing changes in the shape of red blood cells and reducing platelet aggregation, reducing the adhesion of red blood cells into the blood vessel wall, reducing capillary spasms.

Impact on red blood cells: In patients with sickle cell anemia, Piracetam improve the shape of the red blood cell membrane, reduce blood viscosity, and prevent red blood cells.

Operate on platelets: In an open study in a healthy volunteer and in patients with Raynaud, increasing the dose of Piracetam to 12g, reducing platelet function depends on dosage when compared to the values before treatment (checking the collection by ADP, Collagen, Epineephrin and releasing βTG), does not significantly change the amount of platelet quantity. In these studies, Piracetam extends the hemorrhage time.

Impact on blood vessels: In animal studies, Piracetam inhibits vascular spasms and interacts with the effects of many drugs that cause vascular spasms. Piracetam has no vasodilation effect, does not cause current changing, bleeding or reducing blood pressure.

Acting on coagulation factors: In healthy volunteers, compared to the value before treatment, piracetam at a dose of 9.6g reduces the plasma concentration of fibrinogen and the Willebrand elements (VIII: C; VIII R: AG; VIII) is about 30 to 40%, and increases bleeding time.

In healthy volunteers, Piracetam reduces the adhesion of red blood cells into the endothelium of the blood vessel wall and stimulates prostacyclin synthesis in healthy endotheliality.

In patients with primary and secondary Raynaud phenomenon, compared to the values before treatment, Piracetam used a dose of 8g/day for 6 months will reduce the plasma concentration of fibrinogen and the Willebrand elements (VIII: C; VIII R: AG; VII;

pharmacokinetic

absorption

Piracetam is absorbed quickly and almost completely. Oral bioavailability, evaluation according to charge under the concentration curve (AUC) is nearly 100% for hard capsules, tablets and solutions. Peak concentration and AUC proportional to the dose.

Distribution

Piracetam's distribution volume is 0.7 l/kg, and the semi -excreted time in plasma is 5 hours in young men. Piracetam through cerebral vascular and placenta, diffuse through artificial kidney dialysis.

Metabolism

So far, piracetam metabolic has not been found.

Elimination

Piracetam is excreted into almost complete urine. Piracetam clearance depends on the clearance of the kidneys, and therefore will reduce the renal failure.

Before taking Lilonton medicine 1000mg/5ml Siuguanchem Symptomatic treatment of mental syndrome (10 tubes)

How to use

Use intravenously.

Dosage

Adults

Symptomatic treatment of mental syndrome - entity

Daily dose is recommended from 2.4 to 4.8g, divided into 2-3 times.

Treatment of muscle vibration causes of the cerebral cortex

Start the daily dose of 7.2g, then increase 4.8g every 3-4 days to a maximum of 20g, divided into 2-3 times. Treatment with other muscle vibration drugs should be maintained at the same dose. Depending on the clinical benefits achieved, the dose should be reduced, if possible. The dose must be determined for each patient by trying treatment.

Once you have started, it is advisable to continue treating with Piracetam as long as the cerebral disease still exists. In patients with an acute attack, the disease may progress well after a while, and so every 6 months should try reducing the dose or stopping treatment. Should be reduced by 1.2g of Piracetam every 2 days (every 3 or 4 days in the event of a Lance - Adams syndrome) to prevent the possibility of convulsions due to suspension or suddenly recurrence.

Dizziness treatment

Daily dose is recommended in the range of 2.4 to 4.8 g, divided into 2-3 times.

Preventing and reducing the exacerbations in sickle cell disease

Daily dose is recommended to prevent exacerbations of 300 mg/kg, using intravenous lines, divided into 4 times.

When taking a dose of less than 160 mg/kg/day or uneven use, it can lead to recurrence of acute attacks.

Children

Symptomatic treatment is difficult to read, combined with appropriate measures such as language therapy

recommended doses for children in school age (from 8 years old) and adolescents are 3.2 g/day, divided into 2 times.

Preventing and reducing the exacerbations in sickle cell disease

In children 3 years of age and older, the prevention of exacerbations is 160 mg/kg/day, divided into 4 times. In case of reducing exacerbations, taking a dose of 300 mg/ kg/ day, intravenous line, divided into 4 times.

When taking a dose of less than 160 mg/kg/day or uneven use, it can lead to recurrence. Piracetam can be used for children with sickle cell anemia under the recommended daily dose (mg/ kg - see above). Piracetam has been used in a few children aged 1-3 years old.

Elderly

Should adjust the dose in the elderly with kidney function damage (see warning and caution, patients with renal impairment below). When long -term treatment in the elderly, the regular evaluation of creatinine should be assessed to adjust the appropriate dose.

Patients with renal failure

Contraindicated to use piracetam for patients with severe renal impairment (creatinine clearance below 20 ml/min).

Daily dose is calculated for each patient by kidney function. Please refer to the table below and adjust the dose as instructed. To use this dose table, the patient's creatinine clearance is estimated (CLCR) is calculated by ml/min. It is possible to estimate creatinine clearance (ml/min) from serum creatinine (mg/dl) through the following formula:

Creatinine clearance (ml/min) 79 2/3 of the daily dose daily, divided into 2-3 times The time

End-stage kidney disease

- Contraindicated

No dose adjustment in patients only has liver failure. Recommendations for dose adjustments in patients with liver and renal failure (see the dose adjustment in patients with renal failure above).

What to do when overdose?

Symptoms:

There is no more harmful effect due to Piracetam overdose.

There has been a report in the case of the highest overdose of 75g.

Treatment:

Excessive overdose, may be gastrointestinal or vomiting. There is no specific antidote for Piracetam overdose. Overdose treatment, may be symptomatic treatment and can be artificial kidney. Effective piracetam type with artificial kidney dialysis is 50 - 60% of the dose.

What to do when forgetting a dose?

Side Effects

When using Lilonton Injection 1000 mg/5 ml, you may experience unwanted effects (ADR).

Unwanted effects are reported in clinical trials and after being put on the market listed in organ groups and frequency of appearance. The frequency is defined as follows: Very common (≥ 1/10); Usually (≥ 1/100,

The data after bringing the drug to the market is not enough to evaluate the ratio.

Blood and lymphatic disorders:

Unknown ratio: bleeding disorders.

immune system:

Unknown ratio: Anaphylactic reaction, sensitivity.

Mental disorders:

Normal: anxiety.

less: depression.

Unknown ratio: agitation, anxiety, vague, hallucinations.

Nervous system disorders:

Normal: hyperactivity.

Little: Insomnia.

Unknown ratio: Air conditioning loss, balance loss, more severe epilepsy, headache, insomnia.

Disorders of ear and vestibular disorders:

Unknown ratio: dizziness.

Gastrointestinal disorders:

Unknown ratio: abdominal pain, upper abdominal pain, diarrhea, nausea, vomiting.

Skin and subcutaneous disorders:

Unknown ratio: angioedema, dermatitis, itching, urticaria.

General disorders and injection site:

Little: weakness.

Testing, other disorders:

Normal: weight gain.

Warnings

This drug is only used by a doctor.

Do not use overdue drugs indicated on the packaging.

Do not use the prescribed overdose.

Notify the doctor with unwanted effects when using the drug.

If you need more information, please consult a doctor.

Contraindicated

Lilonton Injection 1000mg/5ml contraindications in the following cases:

Hypersensitivity to Piracetam, Pyrolidone derivatives or any excipients.

Huntington dance syndrome.

Severe renal failure (creatinine clearance below 20 ml/minute).

Brain hemorrhage.

Precautions for use

Because Piracetam affects the collection of platelets, it is cautious when used for patients with severe bleeding, patients are at risk of bleeding such as gastrointestinal ulcer, patients with hematurian disorders, patients with a history of hemorrhagic hemorrhage, patients with large surgery including teeth, and patients taking anticoagulants, anti -platelet drugs including low -dose Aspirin.

kidney failure

Piracetam is eliminated through the kidneys, so be careful with cases of renal failure.

Elderly

When long -term treatment for the elderly, the evaluation of creatinine is needed to adjust the dose if necessary.

Stop drugs

Should avoid sudden stop use of the drug, due to causing muscle vibration or seizures.

The ability to drive and operate machinery

In clinical trials, at the dose of 1.6 - 15 g/day, there is a report on hyperactivity, drowsiness, anxiety, depression in patients using piracetam compared to Placbo. There is no testing test at the dose of 15 - 20 g/day. So be cautious in patients who want to drive or operate machinery while using piracetam.

Pregnancy

There is no sufficient data on the use of piracetam in pregnant women. Animal studies show that Piracetam does not directly or indirectly to pregnancy, embryo or fetal development, near birth or after birth.

Piracetam passes the placenta. The drug concentration in infants is about 70 - 90% of the mother's concentration. Piracetam should not be used during pregnancy unless it is really necessary, when the benefit is more than the risk and when the clinical condition of pregnant women need to be treated with piracetam.

Breastfeeding period

Piracetam is excreted into breast milk. Therefore, piracetam should not be used when breastfeeding or breastfeeding must be stopped when treated with piracetam. It is necessary to decide to stop breastfeeding or stop using piracetam, depending on the benefits of breastfeeding with babies and the benefits of mother treatment.

Medicinal interaction

pharmacokinetic interaction

Piracetam's pharmacokinetic change ability is thought to be low, because about 90% of the dose is excreted in the urine in the form of unchanged.

In vitro, Piracetam does not inhibit the types of cytochrome p450 in CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 4A9/11 at concentrations 142, 426 and 1422 µg/ml.

At 1422µg/ml concentration, it has a very light inhibitory effect on the form of CYP 2A6 (21%) and 3A4/5 (11%). However, the ki value of these two types of inhibition is very good at concentration of 1422µg/ml. Therefore, Piracetam has no metabolic interaction with other drugs.

thyroid hormone

There have been reports on vague, stimulation and sleep disorders when treated simultaneously with thyroid hormones (T3 + T4).

acenocoumarol

In a single blind study in patients with severe recurrent vein thrombosis, using 9.6 g piracetam/day without changing the necessary dose of acenocoumarol to achieve the INR index at 2.5 to 3.5; But compared with the effect when only using acenocoumarol, the use of piracetam 9.6 g/day significantly reduces platelet aggregation, release β-thrombogulin, fibrinogen levels and Willbrand elements (VIII: C; VIII: VW: AGI: VW: RCO)

anti -epileptic drugs

Use Piracetam 20 g/day for 4 weeks does not change the maximum and minimum concentration of anti -epileptic drugs (phenytoin, carbamazepine, phenobarbital, valproate) in epilepsy patients taking drugs in stable dose.

alcohol

Using alcohol and does not affect the serum concentration of piracetam, the alcohol concentration is not affected when using piracetam at a dose of 1.6g.

Storage

In a dry place, the temperature does not exceed 30 ° C. Avoid light.

To be out of reach of children.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.